Form 4: Dare Bioscience Director Jessica D. Grossman Acquires Stock Options

Jessica D. Grossman, a director of Dare Bioscience, acquired stock options for 40,000 shares on June 5, 2024.

Summary

• Jessica D. Grossman, a director at Dare Bioscience, acquired stock options to purchase 40,000 shares of common stock on June 5, 2024.
• The exercise price of these options is $0.43 per share.
• The options vest on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to continued service as a director.
• The options will become exercisable in full upon a change in control of the issuer.
• Following the transaction, Ms. Grossman beneficially owns 40,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard stock option grant to a director. It indicates confidence but doesn't provide significant positive or negative news.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting and exercisability of the options are contingent upon continued service as a director and a potential change in control of the issuer.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of directors and shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry to incentivize performance and align interests with shareholders.
• The vesting schedule, contingent on continued service and a change in control, is typical for such grants.
• Comparable companies often use similar equity-based compensation plans to attract and retain talent.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates